American Society of Clinical Oncology

Radhakrishnan Ramchandren MD, highlights the recent US Food and Drug Administration’s (FDA) approval and advantages of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for advanced stage, classic Hodgkin lymphoma.

The phase 3 iNNOVATE trial finds ibrutinib in combination with rituximab to be safe and effective in relapsed/refractory and treatment-näive patients with Waldenström’s macroglobulinemia.

Researchers present promising phase 2 data regarding tazemetostat for malignant mesothelioma, the first reported clinical data of an EZH2 inhibitor in these patients.

Manuel Litchman, MD, President and CEO of Mustang Bio Inc, highlights the advantages of using CAR-T therapies as treatments for rare cancers.

E. Anders Kolb, MD, Director of Nemours Center for Cancer and Blood Disorders at Nemours/Alfred I. duPont Hospital for Children, explains the importance of teaching resiliency as an educational tool and addressing the psychosocial burdens placed on patients in pediatric oncology.

Researchers release updated data from the phase 3 ALEX trial comparing alectinib with crizotinib as first-line treatment against ALK-positive non-small cell lung cancer.

Manmeet Ahluwalia, MD, Head of Operations in the Brain Tumor Center at Cleveland Clinic, explains what a team approach should look like when treating brain tumors and other rare cancers.

Researchers find that the use of PET scans at baseline and after induction therapy can help them tailor chemotherapy regimens in esophageal cancer patients, increasing survival.

Owen A. O’Connor, MD, PhD, Director of Center for Lymphoid Malignancies at Columbia University, emphasizes the importance of sharing experiences among physicians and researchers in the rare diseases like peripheral T-cell lymphomas.

Manmeet Ahluwalia, MD, Head of Operations in the Brain Tumor Center at Cleveland Clinic, discusses the importance of team approaches when treating brain tumors and other rare cancers.

Researchers report positive results for phase 1 trial of ivosidenib in patients with IDH1+ acute myeloid leukemia.

Results of a recent study demonstrate that treatment at a specialized cancer center is associated with better leukemia-specific survival in children, adolescents, and young adults.

A new phase 3 clinical trial boasts highest survival rates of these T-cell malignancies.

First-in-man phase 1 trial meets its primary endpoints by demonstrating safety and immunogenicity of a mutation-specific IDH1R132H peptide vaccine.

To date, OPTIMISMM is the only phase 3 study in early RRMM to report a significantly and clinically meaningful PFS improvement in LEN-exposed patients.

Prospective genomics can inform subsequent clinical trial analysis aiming at matching outcome with tumor genotyping.

Wellstat Therapeutics has developed vistonuridine, the first viable prodrug of uridine, which is an orally administered agent that delivers approximately 8-fold more uridine as it is converted to uridine in the body than administration of uridine itself.

Early chemotherapy for relapsed ovarian cancer based on serial monitoring of CA-125 levels failed to improve overall survival or quality of life compared with delayed therapy according to clinical signs and symptoms of relapse in a large European trial.

Researchers at Fox Chase Cancer Center in Philadelphia, PA, believe the experimental drug neratinib may offer a new treatment option for women with HER2-positive breast cancer.

In what researchers from the University Hospital in Madrid, Spain, are calling a practice-changing study, sequential treatment with chemotherapy followed by chemoradiotherapy more than doubled time-to-treatment failure in patients with unresectable locally advanced head and neck cancer.

Dr. Hussein Tawbi and colleagues decided to look for biomarkers that might predict response to alkylator-based chemotherapy used to treat metastatic melanoma. They identified eight genes that they believe may form a profile useful in distinguishing responders from nonresponders.

A new retrospective study shows that use of three widely prescribed selective serotinin reuptake inhibitors—Prozac, Paxil, and Zoloft—more than double the risk of breast cancer recurrence in women treated with tamoxifen.

Previous studies have found oral human papillomavirus infection to be a strong risk factor for oropharyngeal cancer.

One of the common assumptions in oncology treatment is that earlier detection and treatment is better and leads to improved survival and outcomes for patients, but does this hold true in reality?

More than 1 million new cases of gastric cancer are diagnosed annually worldwide. The prognosis for patients with this disease is poor, and new treatments with the potential to offer even small improvements in survival can be practice-changing.

Approximately 15% of breast cancers are triple negative, with a higher incidence of this cancer subtype found in black and Hispanic women and those younger than 40 years. Triple-negative breast cancers are aggressive and difficult to treat, leading to higher rates of metastases and poorer survival than for other breast cancers.

A national survey found that oncologists do not address fertility issues as adequately as they should with discussions, provision of educational materials, and referrals to reproductive specialists despite 30% to 80% of all patients with cancer being at risk for infertility.

A customized vaccine using a patient’s own tumor cells called BiovaxID, prolonged disease-free survival in patients with follicular lymphoma who maintained complete remission after chemotherapy for one year and were then treated with the vaccine.

Last month the news that Roche�s drug bevacizumab (Avastin) failed to improve disease-free survival in a trial of patients with early stage colon cancer made a big media splash. Norman Wolmark, MD, Allegheny General Hospital, Pittsburgh, Pennsylvania, addressed the study�s full results in a press conference the day before a scheduled plenary presentation at ASCO.

A new study from Memorial Sloan-Kettering Cancer Center indicates that the majority of patients who present with stage IV colorectal cancer do not require immediate surgery to remove their primary tumor.